Bioventus, Inc. Class A (BVS)

NASDAQ:
BVS
| Latest update: Apr 15, 2026, 5:26 PM

Stock events for Bioventus, Inc. (BVS)

Over the past six months, Bioventus's stock price has been impacted by several events. The Third Quarter Financial Results led to a significant increase of +15.09% in its stock price. The Fourth Quarter and Full Year 2025 Financial Results announcement resulted in a stock price jump of +7.44% following an earnings beat and positive guidance. Several analysts upgraded their price targets and ratings for Bioventus following the strong Q4 2025 results and positive FY2026 guidance. Bioventus Inc. was added to the S&P Healthcare Equipment Select Industry Index. There have been instances of insider selling over the past 90 days.

Demand Seasonality affecting Bioventus, Inc.’s stock price

The provided information does not explicitly detail any demand seasonality for Bioventus's specific products and services. The company reports global revenue for its Pain Treatments, Surgical Solutions, and Restorative Therapies, and tracks growth on both reported and organic bases, but does not specify seasonal fluctuations in demand for these product categories.

Overview of Bioventus, Inc.’s business

Bioventus Inc. is a medical technology company established in 2012, headquartered in Durham, North Carolina, operating within the Healthcare Equipment & Supplies sector. It focuses on developing and commercializing minimally invasive treatments that enhance the body's natural healing processes. The company's product portfolio includes Pain Treatments, Restorative Therapies, and Surgical Solutions. Major products include non-surgical pain injection therapies like DUROLANE and peripheral nerve stimulation products, products for minimally invasive fracture treatments including the EXOGEN Bone Stimulation System, and bone graft substitutes to stimulate bone healing in orthopedic surgeries, and ultrasonic products for precise bone cutting, sculpting, and soft tissue management. The Advanced Rehabilitation Business was divested at the end of 2024.

BVS’s Geographic footprint

Bioventus has a global presence, with its corporate headquarters in Durham, NC, and additional offices in Memphis, TN; Valencia, CA; Farmingdale, NY; and Mississauga, Ontario, Canada. Its international headquarters are located in Hoofddorp, The Netherlands. The company operates in more than 50 countries worldwide, with key revenue derived from both the United States and international markets.

BVS Corporate Image Assessment

In the past year, Bioventus has maintained a generally positive to neutral brand reputation, as indicated by a news sentiment score of 0.67. Positive news and analyst coverage have highlighted strong demand for products like DUROLANE in the United States and the successful execution of the EXOGEN bone stimulation system. There is no specific information detailing events that have negatively impacted Bioventus's brand reputation in the past year.

Ownership

Bioventus's ownership is predominantly held by institutional investors, who collectively hold between 62.94% and 69.89% of the shares. Major institutional owners include Essex Woodlands Management, Inc., Juniper Investment Company, LLC, Nantahala Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc, Royce & Associates Lp, Geode Capital Management, Llc, Kent Lake PR LLC, State Street Corp, and American Century Companies Inc. Individual shareholders account for a smaller percentage, ranging from 2.27% to 14% of ownership. Insiders own approximately 33% of the stock. Smith & Nephew plc also retains a 9.53% stake in the company.

Expert AI

Show me the sentiment for Bioventus, Inc.
What's the latest sentiment for Bioventus, Inc.?

Price Chart

$10.36

4.56%
(1 month)

Top Shareholders

Essex Woodlands Management, Inc.
19.44%
Juniper Investment Co. LLC
10.36%
Nantahala Capital Management LLC
9.03%
BlackRock, Inc.
4.66%
The Vanguard Group, Inc.
4.46%
Franklin Resources, Inc.
1.97%
Geode Holdings Trust
1.67%
Nomura Holdings, Inc.
1.67%

Trade Ideas for BVS

Today

Sentiment for BVS

News
Social

Buzz Talk for BVS

Today

Social Media

FAQ

What is the current stock price of Bioventus, Inc.?

As of the latest update, Bioventus, Inc.'s stock is trading at $10.36 per share.

What’s happening with Bioventus, Inc. stock today?

Today, Bioventus, Inc. stock is up by 4.56%, possibly due to news.

What is the market sentiment around Bioventus, Inc. stock?

Current sentiment around Bioventus, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Bioventus, Inc.'s stock price growing?

Over the past month, Bioventus, Inc.'s stock price has increased by 4.56%.

How can I buy Bioventus, Inc. stock?

You can buy Bioventus, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol BVS

Who are the major shareholders of Bioventus, Inc. stock?

Major shareholders of Bioventus, Inc. include institutions such as Essex Woodlands Management, Inc. (19.44%), Juniper Investment Co. LLC (10.36%), Nantahala Capital Management LLC (9.03%) ... , according to the latest filings.